Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model
Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patient...
Main Authors: | Vanesa Gutiérrez Calderón, Alexandra Cantero González, Laura Gálvez Carvajal, Yolanda Aguilar Lizarralde, Antonio Rueda Domínguez |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920984061 |
Similar Items
-
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy
by: Hirofumi Shibata, et al.
Published: (2021-09-01) -
Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer
by: Shuaibo WANG, et al.
Published: (2020-05-01) -
Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2020-01-01) -
Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
by: Guocan Yu, et al.
Published: (2021-01-01) -
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC
by: Jay M. Lee, MD, et al.
Published: (2021-10-01)